

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 4, 2019**

**Cocrystal Pharma, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other Jurisdiction  
of Incorporation)

001-38418  
(Commission  
File Number)

35-2528215  
(IRS Employer  
Identification No.)

19805 N. Creek Parkway  
Bothell, WA  
(Address of principal executive offices)

98011  
(Zip Code)

Registrant's telephone number, including area code: (786) 459-1831

(Former name or former address, if changed since last report.): N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  
**(d)**

On April 4, 2019, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Dr. Anthony Japour as a director to fill a vacancy on the Board, effective immediately. Dr. Japour was designated by Dr. Raymond Schinazi, our principal stockholder, pursuant to the Stockholder Rights Agreement, dated November 24, 2014. Dr. Japour was also appointed as a member of the Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately.

Anthony Japour, M.D., 59, has served as a Medical Director of ICON plc, a global provider of outsourced drug development and commercialization solutions and services to the pharmaceutical, biotechnology, medical device and government and public health organizations, since February 2016. Prior to that, from April 2012 to February 2016, Dr. Japour worked as an internal medicine physician at Elite Health Medical Group in Miami, Florida, where he specialized in infectious diseases. Dr. Japour is also the owner and director of Anthony Japour and Associates, Medical and Scientific Consulting, Inc., a medical and scientific consulting firm he established in November 2006.

There are no related party transactions between the Company and Dr. Japour reportable under Item 404(a) of Regulation S-K.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cocrystal Pharma, Inc.**

Date: April 9, 2019

By: /s/ James Martin  
Name: James Martin  
Title: Chief Financial Officer

---

